EGFR and colorectal carcinoma: A previous study revealed that lapatinib, an EGFR/HER-2 kinase inhibitor, combined with Panobinostat, a histone deacetylase inhibitor, interacted synergistically to inhibit the proliferation and colony formation in all CRC cell lines tested.